Cargando…
Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
PURPOSE: Ceftazidime–avibactam is a novel β-lactam/β-lactamase inhibitor combination recently approved in Europe and the USA for the treatment of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), among other indications. In the phase III REPROVE trial (NCT01808...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223046/ https://www.ncbi.nlm.nih.gov/pubmed/31836928 http://dx.doi.org/10.1007/s00228-019-02804-z |